Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
Want to see GALT full AI Analyst Report?
Top Page
Galectin Therapeutics
(NASDAQ:GALT)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.50
▼(-56.22% Downside)
Action:ReiteratedDate:04/08/26
The score is weighed down primarily by weak financial performance (no revenue, ongoing losses/cash burn, and a stressed balance sheet with negative equity and rising debt). Technicals also remain bearish with the stock trading below key moving averages and negative MACD. Valuation signals are limited due to losses and no dividend, while the recent board addition is a modest positive but not enough to offset the core financial and trend risks.
Positive Factors
Targeted galectin‑3 pipeline
Galectin’s pipeline centers on a defined, mechanism-based approach (galectin-3 inhibition) with lead candidate belapectin targeting NASH cirrhosis and portal hypertension. A clear, differentiated biological target and focus on fibrotic liver disease support durable clinical value if trials succeed and address a large unmet need.
Negative Factors
Pre‑revenue development profile
The company has no product revenue and posts substantial, recurring net losses. Long-term viability therefore hinges entirely on successful clinical outcomes, regulatory approvals, or partner deals; failure or delay in those catalysts would materially impair prospects and leaves limited operating resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted galectin‑3 pipeline
Galectin’s pipeline centers on a defined, mechanism-based approach (galectin-3 inhibition) with lead candidate belapectin targeting NASH cirrhosis and portal hypertension. A clear, differentiated biological target and focus on fibrotic liver disease support durable clinical value if trials succeed and address a large unmet need.
Read all positive factors
Galectin Therapeutics (GALT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$150.74M
Dividend YieldN/A
Average Volume (3M)341.94K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue GrowthN/A
EPS Growth35.99%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding65,827,446
10 Day Avg. Volume287,288
30 Day Avg. Volume341,945
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap1.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.21
Forecast
1Y Price Target
$11.00Price Target Upside92.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Galectin Therapeutics Business Overview & Revenue Model
Company Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibit...
How the Company Makes Money
As a clinical-stage biotechnology company, Galectin Therapeutics does not have publicly established, recurring product revenue from commercialized drugs; its business model is primarily centered on advancing drug candidates through clinical trials...
Galectin Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -37.00K | -33.00K | -32.00K | -41.00K |
| EBITDA | -23.45M | -41.47M | -38.24M | -37.71M | -30.00M |
| Net Income | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M |
Balance Sheet | |||||
| Total Assets | 19.53M | 17.50M | 28.20M | 21.29M | 41.83M |
| Cash, Cash Equivalents and Short-Term Investments | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M |
| Total Debt | 133.74M | 106.25M | 71.81M | 39.87M | 29.06M |
| Total Liabilities | 145.73M | 120.56M | 88.44M | 53.48M | 39.21M |
| Stockholders Equity | -126.19M | -103.07M | -60.24M | -32.19M | 2.62M |
Cash Flow | |||||
| Free Cash Flow | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Operating Cash Flow | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 26.48M | 31.23M | 40.03M | 10.00M | 36.81M |
Galectin Therapeutics Technical Analysis
Negative
5.71
Price Trends
2.81
Negative
3.59
Negative
3.95
Negative
Market Momentum
-0.15
Negative
44.92
Neutral
47.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Negative. The current price of 5.71 is above the 20-day moving average (MA) of 2.57, above the 50-day MA of 2.81, and above the 200-day MA of 3.95, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 44.92 is Neutral, neither overbought nor oversold. The STOCH value of 47.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GALT.
Galectin Therapeutics Risk Analysis
Galectin Therapeutics disclosed 38 risk factors in its most recent earnings report. Galectin Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galectin Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.07B | 3.16 | 1.71% | ― | ― | 90.50% | |
58 Neutral | $1.21B | -4.04 | -64.64% | 14.68% | ― | 93.63% | |
52 Neutral | $556.73M | -4.97 | -26.87% | ― | ― | 50.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $234.00M | -2.10 | -51.35% | ― | -49.53% | -81.33% | |
44 Neutral | $171.43M | -1.35 | -85.20% | ― | ― | 52.32% | |
43 Neutral | $150.74M | -12.08 | 25.65% | ― | ― | 35.99% |
* Healthcare Sector Average
GALT
Galectin Therapeutics
2.29
0.93
68.38%
OMER
Omeros
14.91
8.57
135.17%
VYGR
Voyager Therapeutics
3.88
0.63
19.38%
TECX
Tectonic Therapeutic
29.65
10.73
56.71%
JBIO
Jade Biosciences
24.52
14.43
143.01%
TNYA
Tenaya Therapeutics
0.79
0.32
69.53%
Galectin Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board
Positive
Mar 17, 2026
On March 12, 2026, Galectin Therapeutics appointed internationally recognized neurosurgeon-scientist Dr. Henry Brem to its Board of Directors as an independent director, with the move announced publicly on March 17, 2026. Brem, a long-time Johns H...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.